U.S., May 17 -- ClinicalTrials.gov registry received information related to the study (NCT06976476) titled 'Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia' on May 08.
Brief Summary: The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).
Study Start Date: May 08
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Hypogammaglobulinemia
Hypogammaglobulinemia, Acquired
Intervention:
DRUG: IgPro20
Will be administered in addition to Standard of Care treatment. IgPro20 is intended for subcutaneous administration using an infusion pump
Recruitmen...